Katy Beckermann, MD, PhD, of Vanderbilt-Ingram Cancer Center, and David Braun, MD, PhD, of Yale School of Medicine, review recent findings from a study on the JAVELIN Renal 101 trial, focusing on the impact of avelumab and axitinib treatment on kidney cancer.
They also highlight correlations between immune populations, T-cell receptor repertoire, and specific biomarkers like memory B cells and cytokine levels.
